ADAP - Adaptimmune Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Cash flows from operating activities
Net Income
-99,430
-95,514
-70,138
-71,579
Depreciation & amortization
7,982
7,810
5,423
3,286
Deferred income taxes
-
-
-
-
Stock based compensation
14,466
16,202
10,804
8,821
Change in working capital
-23,070
-45,343
7,208
12,496
Accounts receivable
-
-5,162
-
-
Inventory
-
-
-
-
Accounts Payable
-
-40,923
-
-
Other working capital
-95,800
-109,096
-79,327
-60,953
Other non-cash items
68
237
341
-1,191
Net cash provided by operating activites
-92,117
-104,388
-54,315
-48,168
Cash flows from investing activities
Investments in property, plant and equipment
-3,683
-4,708
-25,012
-12,785
Acquisitions, net
-
-
-
-
Purchases of investments
-133,214
-150,787
-171,334
-42,837
Sales/Maturities of investments
121,645
138,038
69,715
73,377
Other investing activites
-
-
22,625
30,540
Net cash used for investing activites
-15,252
-17,457
-126,081
17,755
Cash flows from financing activities
Debt repayment
-
-
-
0
Common stock issued
-
99,653
103,167
0
Common stock repurchased
-
-
-
-
Dividends Paid
-
-
-
-
Other financing activites
-
-
-
0
Net cash used privided by (used for) financing activities
100,632
102,690
103,568
17
Net change in cash
-
-
-74,500
-35,975
Cash at beginning of period
46,507
88,296
162,796
198,771
Cash at end of period
39,770
72,476
88,296
162,796
Free Cash Flow
Operating Cash Flow
-92,117
-104,388
-54,315
-48,168
Capital Expenditure
-3,683
-4,708
-25,012
-12,785
Free Cash Flow
-95,800
-109,096
-79,327
-60,953